Acticoat Antimicrobial Barrier Dressing utilizing advanced silver technology to help create an optimal wound environment.

Features

• Rayon/polyester core helps manage moisture level and control silver release.
• Silver-coated high-density polyethylene mesh facilitates the passage of silver through the dressing.
• The nanocrystalline coating of pure silver delivers antimicrobial barrier activity within 30 minutes - faster than other forms of silver.
• NUCRYST Pharmaceutical's antimicrobial technology can produce silver-coated polyethylene films that can release an effective concentration of silver over several days. Thus, as silver ions are consumed, additional silver is released from the dressing to provide an effective antimicrobial barrier. This patented silver-based antimicrobial technology can be applied to a wide range of medical devices including wound dressings, certain types of catheters, and various implants to prevent infection. This technology was first applied to burn wound dressings because burns present a very severe risk of infection

Benefits

• Delivers fast-acting, long-lasting antimicrobial barrier control.
• Effective barrier which may assist in preventing contamination of the wound.
• ACTICOAT 7 is cost-effective because it can be left on wounds for up to 7 days.
• ACTICOAT 7 is versatile. The dressings can be cut to the desired shape and size to wrap around all body parts.
• The sustained release of silver also means fewer dressing changes, resulting in less exposure of the wound bed to the environment. This reduces the risk of infection, which lowers hospital costs.
• Laboratory studies show that the ACTICOAT 7 dressing kills micro-organisms faster than conventional products such as silver sulfadiazine (1 percent cream) or silver nitrate (0.5%) solution. It has also been shown in-vitro to provide protection against more than 150 pathogens. The pathogens tested in the lab include very resistant strains of bacteria such as antibiotic-resistant strains of Pseudomonas, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and fungi. These pathogens have been known to sweep through a hospital and infect a great many patients with already weakened immune systems. Infections contracted during hospitalization caused by these so-called superbugs and other organisms cost North American taxpayers an estimated $18 billion a year in additional hospital care.

precautions

• For external use only.
• Do not use if product color is not uniform.
• Do not use contents if pack is opened or damaged.
• Avoid exposure to temperatures above 50 degrees C. Protect from light.
• ACTICOAT 7 is not compatible with oil-based products, such as petrolatum.
• Avoid contact with electrodes or conductive gels during electronic measurements, e.g. EEG and ECG.
• In patients undergoing MRI (Magnetic Resonance Imaging) ACTICOAT must be removed from the area within the anatomical field being imaged. If ACTICOAT is being used on any area not within the image field, it may remain in place during the MRI.